Sunshine Biopharma, Inc., a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals announced that it has moved its headquarters to New York City.
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has moved its headquarters to New York City. The Company’s Head Office is now located at 1177 Avenue of the Americas, 5th Floor, New York, NY 10036 (Tel: 332-216-1147). The Company will maintain a satellite office at its previous headquarters in Montreal (Canada) at 6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, Quebec, Canada, H9R 0A5 (Tel: 514-426-6161). The Company’s email address (info@sunshinebiopharma.com) and URL (www.sunshinebiopharma.com) have not changed.
AboutSunshineBiopharma
Sunshine Biopharma is a pharmaceutical company operating a Canadian wholly owned subsidiary (Nora Pharma Inc.) with 41 employees and 51 generic prescription drugs on the market in Canada. The Company is planning to expand its product offering to a total of 67 generic prescription drugs by the end of 2024. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA for liver cancer, and (ii) PLpro protease inhibitor for COVID-19. For more information, please visit: www.sunshinebiopharma.com.
SafeHarborForward-LookingStatements
Thispressreleasecontainsforward-lookingstatementswhicharebasedoncurrentexpectations,forecasts,and assumptionsofSunshineBiopharma,Inc.(the“Company”)thatinvolverisksaswellasuncertaintiesthatcouldcause actualoutcomesandresultstodiffermateriallyfromthoseanticipatedorexpected. Thesestatementsappearinthis releaseandinclude allstatements thatarenotstatements ofhistoricalfactregardingtheintent,belieforcurrent expectationsoftheCompany,includingstatementsrelatedtotheCompany’s drugdevelopmentactivities,financial performance, andfuturegrowth.Theserisksanduncertainties arefurtherdescribedinfilingsandreportsbythe Company withtheU.S.SecuritiesandExchange Commission(SEC).Actualresults andthetimingofcertainevents coulddiffermateriallyfromthoseprojectedinorcontemplatedbytheforward-lookingstatementsduetoanumberof factorsdetailedfromtimetotimeintheCompany’s filingswiththeSEC.Referenceisherebymadetocautionary statementsandriskfactorssetforthinthe Company’smostrecentSECfilings.
ForAdditionalInformation:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
